| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC90061 | Vx-445(r) | Less active enantiomer of Elexacaftor |
|
| DC90062 | (-)-5-hydroxy-equol | Natural microbial metabolite of isoflavone genistein, increasing the lifespan and improving the thermal and oxidative stress tolerance of C. elegans |
|
| DC90063 | (-)-adenophorine | Moderate alpha-l-fucosidase inhibitor |
|
| DC90064 | (-)-agelastatin A | Inhibitor of Eukaryotic Translation; Antitumor Natural Product |
|
| DC90065 | (-)-antofine | Antitumor agent to be associated with negative regulation of Met endosomal signaling in renal cancer cells |
|
| DC90066 | (-)-astercin | Novel inhibitor of cholesterol transport proteins |
|
| DC90067 | (-)-cm-tpmf | Subtype-selective activator of K(Ca)2.1 |
|
| DC90068 | (-)-gomisin M1 | Natural modulator of miRNA biogenesis, inhibiting the proliferation, migration, and invasion of hepatocellular carcinoma (HCC) cells |
|
| DC90069 | (-)-oxfbd05 | Novel potent inhibitor of the CREBBP/EP300 bromodomain, showing >100-fold selectivity over a representative member of the BET bromodomains, BRD4(1) |
|
| DC90070 | (-)-tetrabenazine Featured | Inhibitor of VMAT-2, decreasing monamines into synaptic vesicles |
|
| DC90071 | (+)-calanolide A | Novel non-nucleoside reverse transcriptase inhibitor (NNRTI) |
|
| DC90072 | (+)-clausenamide | Natural inhibitor of hepatocyte ferroptosis, protecting against drug-induced liver injury |
|
| DC90073 | (+)-isocorydine Hydrochloride | Natural inhibitor of ERK signaling pathways, inhibiting epithelial-mesenchymal transition via STAT3, showing the growth inhibition of HepG2, HeLa and MGC-803 cancer cell lines |
|
| DC90074 | (+)-jnj-bj | Novel TNKS/2 inhibitor, competing with nicotinamide binding to tankyrases |
|
| DC90075 | (+)-mesembrine | Natural highly potent inhibitor of the serotonin transporter (SERT) |
|
| DC90076 | (+)-nd | Novel BRD4 inhibitor, suppressing osteoclastogenesis and ovariectomized osteoporosis by blocking RANKL-mediated MAPK and NF-κB pathways |
|
| DC90077 | (+)-sattabacin | Antiviral activity against Varicella Zoster |
|
| DC90078 | (+)-sj311 | Novel potent anti-malarial agent against multiple resistant strains of P. falciparum in vitro and show no cytotoxicity to mammalian cells |
|
| DC90079 | (+)-tetrabenazine | Catecholamine-depleting agent, actively against the 3 major monoamines in the CNS |
|
| DC90080 | (+)-xylariamide A | Novel probe for mycobacterial and fungal carbonic anhydrase |
|
| DC90081 | (+/-)-marmesin | Novel angiogenesis inhibitor, regulating endothelial cell fate and angiogenesis |
|
| DC90083 | (±)-a-278637 | Novel potassium channel opener |
|
| DC90084 | (±)-clopidogrel Hydrogensulfate | Inhibitor of ADP-induced platelet aggregation; anti-thrombotic |
|
| DC90085 | (±)-doi Hydrochloride | Potent and selective 5-HT2 serotonin receptor agonist |
|
| DC90086 | (±)-gc242 | Novel profluorescent RAMOSUS3 (RMS3) probe with strigolactone-like bioactivity |
|
| DC90087 | (±)-mrjf22 | Novel prodrug of the sigma (σ) ligand haloperidol metabolite II conjugated with the histone deacetylase (HDAC) inhibitor valproic acid, demonstrating antiangiogenic activity |
|
| DC90088 | (1r,2r)-ifenprodil | Potent antagonist of GluN2B-NMDA receptors (Ki = 5.8 nM), inhibiting ion flux in two-electrode voltage clamp experiments (IC50 = 223 nM) |
|
| DC90089 | (1r,3r)-rsl3 | Negative control for RSL3 |
|
| DC90090 | (1s,2s)-cyclopropane-1,2-dicarboxylic Acid | Building Block |
|
| DC90091 | (2,6-aza)trp | Novel water-sensitive probe, demonstrating superior sensitivity for detecting modulation of water microsolvation, structural conformation during oligomer formation and 5FUrd binding to both wild type and mutant SOD1 |
|
